Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Cerulean Doses First Patient in Phase II Study of CRLX101 Drug
Feb. 5, 2013
Cerulean Pharma has dosed the first patient in a Phase II study of its investigational CRLX101 drug, designed for the treatment of extensive-stage small cell lung cancer patients sensitive to first-line platinum-based chemotherapy.
Pharmaceutical Business Review
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing